Literature DB >> 11477143

Epstein-Barr virus infection in paediatric liver transplant recipients: detection of the virus in post-transplant tonsillectomy specimens.

N Meru1, S Davison, L Whitehead, A Jung, D Mutimer, N Rooney, D Kelly, G Niedobitek.   

Abstract

AIMS: Post-transplant lymphoproliferative disease (PTLD) is an important and serious complication in transplant patients. Recent studies have suggested that quantitative assessment of Epstein-Barr virus (EBV) infection in transplant patients might help to identify those at risk of developing PTLD. Therefore, tonsils from paediatric liver transplant recipients were studied for evidence of EBV infection.
METHODS: Tonsils were studied by in situ hybridisation for the detection of the small EBV encoded nuclear RNAs (EBERs). The phenotype of EBV infected cells was determined by double labelling in situ hybridisation and immunohistochemistry. The expression of viral latent and lytic antigens was determined by immunohistochemistry. Tonsils from patients without known immune defects were studied as controls.
RESULTS: Tonsils from transplant patients showed pronounced follicular hyperplasia and minor paracortical hyperplasia. In situ hybridisation revealed variable numbers of EBV infected B cells in the tonsils from transplant patients (range, 2-1000/0.5 cm(2); mean, 434/0.5 cm(2); median, 105/0.5 cm(2)). Lower numbers were detected in the control tonsils (range, 1-200/0.5 cm(2); mean, 47/0.5 cm(2); median, 9/0.5 cm(2)). The latent membrane protein 1 (LMP1) of EBV was not detected and there were only rare cells in two cases showing expression of the EBV encoded nuclear antigen 2 (EBNA2). There was no evidence of lytic infection. None of the patients developed PTLD within a follow up period of up to five years.
CONCLUSIONS: These data indicate that tonsillar enlargement in paediatric liver transplant patients does not necessarily imply a diagnosis of PTLD. Furthermore, the presence of increased numbers of EBV infected cells in tonsils from liver transplant recipients by itself does not indicate an increased risk of developing PTLD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477143      PMCID: PMC1187079          DOI: 10.1136/mp.54.4.264

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  29 in total

1.  Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue.

Authors:  G Niedobitek; H Herbst; L S Young; L Brooks; M G Masucci; J Crocker; A B Rickinson; H Stein
Journal:  Blood       Date:  1992-05-15       Impact factor: 22.113

2.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

3.  Sources of DNA for detecting B cell monoclonality using PCR.

Authors:  T C Diss; L Pan; H Peng; A C Wotherspoon; P G Isaacson
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

4.  Quantitation of Epstein-Barr virus DNA in the blood of adult liver transplant recipients.

Authors:  D Mutimer; N Kaur; H Tang; S Singhal; J Shaw; L Whitehead; A Rickinson; G Niedobitek
Journal:  Transplantation       Date:  2000-03-15       Impact factor: 4.939

5.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

6.  Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease.

Authors:  P S Randhawa; R Jaffe; A J Demetris; M Nalesnik; T E Starzl; Y Y Chen; L M Weiss
Journal:  N Engl J Med       Date:  1992-12-10       Impact factor: 91.245

7.  Epstein-Barr virus in inflammatory diseases of the liver and liver allografts: an in situ hybridization study.

Authors:  S G Hubscher; A Williams; S M Davison; L S Young; G Niedobitek
Journal:  Hepatology       Date:  1994-10       Impact factor: 17.425

8.  The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children.

Authors:  M Ho; R Jaffe; G Miller; M K Breinig; J S Dummer; L Makowka; R W Atchison; F Karrer; M A Nalesnik; T E Starzl
Journal:  Transplantation       Date:  1988-04       Impact factor: 4.939

9.  Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

Authors:  M Ho; G Miller; R W Atchison; M K Breinig; J S Dummer; W Andiman; T E Starzl; R Eastman; B P Griffith; R L Hardesty
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

10.  Epstein-barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.

Authors:  G J Babcock; L L Decker; R B Freeman; D A Thorley-Lawson
Journal:  J Exp Med       Date:  1999-08-16       Impact factor: 14.307

View more
  3 in total

Review 1.  Epstein-Barr virus infection and human malignancies.

Authors:  G Niedobitek; N Meru; H J Delecluse
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

2.  Severe obstructive sleep apnoea due to adenotonsillar hypertrophy after liver transplantation.

Authors:  Omar Mulla; Yogesh Bajaj; Lindsey Knight
Journal:  BMJ Case Rep       Date:  2012-12-04

3.  EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1.

Authors:  Yasodha Natkunam; John R Goodlad; Amy Chadburn; Daphne de Jong; Dita Gratzinger; John K C Chan; Jonathan Said; Elaine S Jaffe
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.